Table 1.
Characteristics of study population.
| Included patient cohort characteristics n = 4,879 | ||||
| Age | Mean (SD) | 64.9 (6.8) | ||
| Median (IQR) | 65 (60–70) | |||
| PSA (ng/ml) | Mean (SD) | 22.7 (41.6) | ||
| Median (IQR) | 13 (7–27) | |||
| <20 μg/l | 2,859 (58.6) | |||
| 20–50 μg/l | 1,415 (29) | |||
| >50 μg/l | 373 (7.6) | |||
| Clinical stage, n (%) | cT1 | 1,755 (36) | ||
| cT2 | 1,245 (25.5) | |||
| cT3 | N.O.S. | 1,830 (37.5) | 745 (15.3) | |
| cT3a | 948 (19.4) | |||
| cT3b | 137 (2.8) | |||
| cT4 | 49 (1.0) | |||
| biopsy Gleason score, n (%) | ≤7 | 2,457 (50.4) | ||
| 8 | N.O.S | 1,466 (30.0) | 143 (2.9) | |
| 3 + 5 | 156 (3.2) | |||
| 4 + 4 | 1,116 (22.9) | |||
| 5 + 3 | 51 (1.0) | |||
| 9 | N.O.S. | 855 (17.5) | 60 (1.2) | |
| 4 + 5 | 608 (12.5) | |||
| 5 + 4 | 187 (3.8) | |||
| 10 | 101 (2.1) | |||
| Follow up (months) | Mean | 60.5 (53.8) | ||
| Median | 48 (21–84) | |||
| min | 0 | |||
| max | 293 | |||
N.O.S, not otherwise specified.